We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+16.08%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$608M
AUM Growth
-$35.2M
Cap. Flow
-$11.5M
Cap. Flow %
-1.89%
Top 10 Hldgs %
60.52%
Holding
49
New
7
Increased
12
Reduced
5
Closed
16

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$15.9M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.5M
3
MRUS
Merus
MRUS
+$14.8M
4
COGT icon
Cogent Biosciences
COGT
+$14.5M
5
KALV
KalVista Pharmaceuticals
KALV
+$14.2M

Top Sells

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$52.6M
2
VRNA
Verona Pharma
VRNA
+$47.5M
3
EYPT icon
EyePoint Inc
EYPT
+$8.74M
4
NUVB icon
Nuvation Bio
NUVB
+$7.64M
5
INSM icon
Insmed
INSM
+$7.55M

Sector Composition

Rank Sector Weight
1 Healthcare 96.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$96M 15.79%
3,006,980
– –
AVBP icon
2
ArriVent BioPharma
AVBP
$1.55B
$54.9M 9.03%
2,059,387
+83,000
+4% +$2.38M
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.72B
$46M 7.57%
2,110,167
+363,500
+21% +$9.35M
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
$33.4M 5.49%
1,993,052
-19,000
-0.9% -$315K
VRNA
5
DELISTED
Verona Pharma
VRNA
$26.5M 4.37%
571,264
-1,263,936
-69% -$47.5M
NUVB icon
6
Nuvation Bio
NUVB
$2.14B
$24.5M 4.03%
9,202,907
-2,968,606
-24% -$7.64M
INSM icon
7
Insmed
INSM
$23.5B
$22.9M 3.77%
332,000
-104,820
-24% -$7.55M
COGT icon
8
Cogent Biosciences
COGT
$6.75B
$21.6M 3.55%
2,763,000
+1,458,000
+112% +$14.5M
SRRK icon
9
Scholar Rock
SRRK
$6.31B
$21.1M 3.47%
+488,000
New +$15.9M
DFTX
10
Definium Therapeutics
DFTX
$5.95B
$21M 3.46%
3,018,000
– –
OCUL icon
11
Ocular Therapeutix
OCUL
$1.97B
$20.7M 3.41%
2,425,000
– –
TSHA icon
12
Taysha Gene Therapies
TSHA
$1.71B
$18.1M 2.97%
10,450,000
+5,877,778
+129% +$12.2M
INSM icon
13
CALL
Insmed
INSM
$23.5B
$17.3M 2.84%
250,000
– –
VRDN icon
14
Viridian Therapeutics
VRDN
$2.06B
$16.7M 2.74%
870,000
– –
GOSS icon
15
Gossamer Bio
GOSS
$81.2M
$16.6M 2.73%
18,350,000
+9,162,117
+100% +$7.85M
DYN icon
16
Dyne Therapeutics
DYN
$3.93B
$15.7M 2.59%
668,000
+405,274
+154% +$12M
PHVS icon
17
Pharvaris
PHVS
$2.46B
$14.9M 2.45%
778,000
+157,530
+25% +$3.24M
CRBP icon
18
Corbus Pharmaceuticals
CRBP
$170M
$13.2M 2.17%
1,115,000
– –
MRUS
19
DELISTED
Merus
MRUS
$13M 2.13%
+308,000
New +$14.8M
ERAS icon
20
Erasca
ERAS
$6.83B
$12.9M 2.12%
+5,136,795
New +$14.1M
BBIO icon
21
BridgeBio Pharma
BBIO
$16.2B
$12.1M 1.99%
441,600
-110,400
-20% -$2.85M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$2.04B
$12M 1.97%
+904,000
New +$15.5M
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$11.6M 1.91%
+1,370,000
New +$14.2M
UNCY icon
24
Unicycive Therapeutics
UNCY
$150M
$7.94M 1.31%
1,000,000
+144,100
+17% +$798K
RGLS
25
DELISTED
Regulus Therapeutics
RGLS
$7.66M 1.26%
4,848,802
+585,101
+14% +$899K
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Octagon Capital Advisors held 49 positions worth $608M, down 5.5% from $643M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Octagon Capital Advisors's Q4 2024 filing shows 7 new, 12 increased, 5 reduced and 16 closed positions. Its largest new stake was Scholar Rock: 488,000 shares worth $21.1M. The largest sale was Structure Therapeutics, an estimated $52.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

  • Octagon Capital Advisors's largest Q4 2024 buy was Scholar Rock: 488,000 shares worth $21.1M.
  • Octagon Capital Advisors added most to Cogent Biosciences in Q4 2024, an estimated $14.5M increase.
  • Octagon Capital Advisors's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $47.5M.
  • Octagon Capital Advisors fully exited Structure Therapeutics in Q4 2024, selling an estimated $52.6M.
  • Octagon Capital Advisors's ten largest holdings make up 61% of its $608M portfolio in Q4 2024.
  • Octagon Capital Advisors opened 7 new positions and closed 16 in Q4 2024.
  • Octagon Capital Advisors's portfolio value fell 5.5% quarter-over-quarter to $608M.

Based on Octagon Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.